Construction of Ru(II) Polypyridyl Based Macrocycles: Synthesis, Characterization, Electrochemical, Li+ Binding, Antitumour and Anti-HIV properties by Mishra, Lallan et al.
MetalBasedDrugs VoL & Nr. 2, 2001
CONSTRUCTION OF Ru(H) POLYPYRIDYL BASED MACROCYCLES:
SYNTHESIS, CHARACTERIZATION, ELECTROCHEMICAL, Li
/ BINDING,
ANTITUMOURAND ANTI-HIV PROPERTIES
Lallan Mishra*, Ragini Sinha and P. C. Pandy
Deparanent ofChemistry, Banaras Hindu University, Varanasi 221 005, India
Abstract
Some ruthenium (II) polypyridyl complexes with a bis-chalconc (obtained by the condensation of 3-mcthyl-
thiophcnc-2-carboxaldchydc and 4-acctyl pyridinc) have bccn synthesized and characterized
spectroscopically (IR, NMR., UV/Vis), conductimetric, elemental analysis and FAB mass data. Their
luminescent, redox and LV binding properties have been studied The anti-HIV and antiturnour activities
have also bccn reported..
Introduction
Studies of ruthenium (II) polypyridyl complexes have been interesting owing to their unique photophysical
and redox characteristics [1]. In fact, these properties have led to the development of new ruthenium
polypyridyl systems either by incorporating the desired groups within the bipyridine moiety itself or by
using other type of donor sites along with the [Ru(bpy/phen)2] core to form mixed ligand tris-chelates
modulating the photo-redox activities of this class of complexes.
Furthermore, it has been reported that Ru(II) complexes bind DNA and a correlation between their binding
affinity and activities have already been established [2,3]. Recently a detailed accounts of such properties of
ruthenium complexes have been reviewed by Clarke et a/.[4]. Based on antiviral [5], antifungal [6],
antibacterial [7] and antitumour [8] activities of chalcones very recently, several Ru(II) complexes bearing
bis-chalcones synthesized by us [9] have been evaluated for their antitumour and anti-HIV activities [10] and
some of them have shown quite interesting properties. It was therelbre considered worthwhile to explore
some new Ru(II) complexes bearing chalcones for the evaluation of their antitumour and anti-HIV properties.
The Li
/ binding properties ofnewly synthesized complexes containing 14-membered ring are also studied.
Materials and Methods
All the solvents purchased from Merck were distilled using standard procedures prior to use. 3-Methyl-
thiophene-2-carboxaldehye, 4-aeetyl pyridine, 2,2’-bipyridine and 1,10-phenanthroline purchased from
Sigma-Aldrich were used as supplied whereas the cis-[Ru(bpy)2Cl2] and cis-pRu(phen)2C12] were prepared by
a reported [11] procedure. Tetra-n-butylammonium bromide supplied by Merck was converted into pure
tetrabutyl ammonium perchlorate (TBAP) by an available procedure [12]. Caution: TBAP could be
explosive so the use of small amounts of it is recommended. Neutral alumina for column chromatography
was supplied by Merck and used as such. All the reactions were carried out under N2 atmosphere
Microanalysis (C, H and N) performed on a Carlo Ebra Elemental Analyzer 1108 and FAB mass data using a
JEOL SX-102 mass spectrometer were earned out at the Central Drug Research Institute, Lucknow, India. IR
(KBr Pellets) and UV/Vis data were obtained using a JASCO FT IR 5300 spectrometer and a Shimadzu UV-
13 1601 spectrophotometer respectively, H and C NMR (DMSO-d6) were recorded on a JEOL FX 90Q
spectrophotometer at B.H.U., Varanasi, India and 1H-1H COSY (DMSO-d6) spectra was recorded at TIFR,
Mumbai, India. Electrochemical measurements were made using an electrochemical interface SI 1287
potentiostat, using a graphite disc as working electrode, a platinium wire auxiliary electrode and Ag/Ag
+
reference electrode in a three electrode configuration. All electrochemical experiments were performed after
bubbling the solution with dinitrogen for 0.25 h. Solution (CHCN) emission spectra were measured at
Umversity of Bristol, UK. The antitumour and anti-HIV activities were evaluated at the School of Pharmacy,
University of North Carolina, USA.
Synthesis of Ligand (L)
The ligand was prepared by addition of a solution of 4-acetyl pyridine (0.02 M, 2.2 mL) in ethanol (5 mL) to
an ethanolic solution (10 mL) of 3-methyl-thiophene-2-carboxaldehyde (0.02 M, 2.2 mL) containing aqueous
NaOH (12 mL, 50%) following reported procedure [5]. After 72 h of stimng distilled water (20 mL) was
added to the reaction mixture and then neutralised with dil HCI (10%). The brick-red precipitate formed was
filtered and washed several times with H20 followed by EtOH and was purified by column chromatography
on alumina with CH3CN as eluent. Two dark red and brown fractions were collected. Minor dark red fraction
was discarded while the major brown fraction was concentrated by evaporation in vacuo. The solid (L) was
crystallized from ethanol and dried in vacuo, M.P. 90 +/- C.
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Synthesis of complexes
[RuL(bpy)2].(PF6)2, (1): An ethanolic solution (10 rnL) of cis-[Ru Copy)2C12] Copy 2,2’-bipyridine) (1 raM,
0.520 g) was mixed to an ethanolic solution (10 mL) of (L) (1 raM, 0.350 g) in a 1:1 molar ratio while
stinhng and the resulting mixture was refluxed for 24 h then cooled to room-temperature and filtered. To the
filtrate, a saturated methanolic solution of NH4PF6 was added. Solid thus obtained was filtered and washed
with H20 and MeOH, and purified on an alumina column with MeCN-saturated aqueous KNO3-water
(7:1:0.5 v/v) as eluent [13]. The eluate was then concentrated to dryness and the residue obtained was
dissolved in minimum volume of acetone followed by the excess addition of methanolie solution of NHFt.
The solid complex (1) was recrystallized (by the addition of diethylether to a solution of complex in acetone)
as crystalline material, M.P. > 250C, yield 40/’0.
[RuL(phen)C12].(PF6)2, (2) was also prepared as reported above by refluxing an ethanolic solution of cis-
[Ru(phen)2Cl2] (where phen 1,10-phenanthroline) (1 raM, 0.532 g) with an ethanolic solution (10 mL) of
(L) (1 mM, 0.350 g).
The elemental analysis and FAB-mass data alongwith other properties of ligand and complexes are shown in
Table I.
Results and Discussion
The synthesis of ligand has been considered in view ofMichael addition [14] (Scheme-I).
H
+ HC--C
3-METItYLTIIO 4.ACETYL I:RIDDIE
2.CARBOXYALDEIYDE
NaOH
MICHAI ADDITION
Scheme I
Table I: Physical, analytical andFAB Mass data of ligand and Ru(II) complexes
Compound
[RuL(bpy)2](PF6)z.2MezCO
[RuL(phen)2](PF6)2.2Me2CO
Analysis found (Calc.)
%C %H
68.03 4.63
(68.%) (4.59)
47.74 3.95
(47.21) (3.93)
49.67 3.90
(49.30) (3:77)
%N Found (Calgd.) (.1 cm2mol-1)
7.95 350 (350)
(8.04) [M]
7.55 908 (908 250
(7.18) [M-PF6"]
7.01 811 (811) 280
,(6.9) [M.-.2PF6]
2+
The micmcrystalline complexes were found thermally stable at room temperature and soluble in acetone,
acetonitrile, methanol, ethanol, DMF and DMSO. The molar conductances of the complexes (CH3CN, 10
-3
M) shown in Table is in agreement with the number of eounteranions present in the complexes [15].
However, the presence of two moles of acetone in the complex has been considered in view of the fitting of
their elemental analysis and observation of a band at 1720 cm
q in their IR spectra.
IR Spectra: In the IR Spectra (KBr) of the complexes a band at 1676 cm" due to the (C=O) was found to
be similar compared to free ligand (1680 cm) which indicates that the >C--O group did not participate in the
bonding with ruthenium. However, peak observed at 1570 em
q in the speetnma of the free ligand due to
pyridyl moiety shifted to 1545 cm
q and 1500 cm
q in the spectrum of complexes (1) and (2) respectively,
indicating that pyridyl group coordinate to ruthenium.
11-I NMR spectra: To get further structural support H NMR spectra of the ligand and its complexes were
recorded in DMSO-d6. The 1H NMR shows (complex) patterns at 5 9.01 8.53, 7.53 7.3, 7.06, 6.86, 2.4,
2.00 ppm due to ortho and meta-protons of both pyridine tings, HC=CH (thiophene), -C-CH, -CHz and -CH3
protons respectively. Its 13C NMR spectrum also showed peaks at 6 185.2 (>C=O), 150.3 (C2 C2’-py), 149.8
(C6, C6’-py), 129.8 (Ca, C4’-py), 128.2 (C3, C3’-py), 126.0 (Cs-thio), 123.8 (C2-thio), 121.8 (C4-thio), 121.7
(C3-thio), 50.6 (-CH2), 48.9 (-CH), 33.4 (-CH3). The 1H NMR spectra of the complexes show resonances at 5
8.75 to 8.6 ppm due to pyridyl protons. Peaks observed in the spectrum of complex (1) at 5 8.34 8.19,
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8.09 8.02, 6 7.9 7.89 and 6 7.61 7.42 ppm were assigned to 3,3’, 4,4’, 5,5’ and 6,6’ protons of the
bipyridine ring and the bands at 6 9.2, 8.6, 8.37, 8.2 7.86 and 7.6 ppm in the spectrum of complex (2) were
assigned to H2/Hg, H4/H7, Hs/H6 and HrtI-Is protons of the phenanthroline ring in agreement with an earlier
report [15t The aH COSY spectrum of one of a representative complex (1) showed that the ortho and meta protons
of both pyridine tings couple with the 6,6’-protons of bipyridine. The COSY spectrum also showed weak
coupling between -CH3 and -CH2 protons supporting the quartet and triplet observed at 6 2.20 and 2.5 ppm
respectively for these protons.
UV-Vb spectra: UV-Vis spectra of the complexes in CH3CN solution (10
-3 M) were recorded m the range
200 800 nm and showed intra-ligand charge-transfer peaks at , 264, 290 (1) and Z, 246 nm (2) whereas
broad peaks observed in the respective spectra at kmx 485 and 417 nm were assigned to the t2g(Ru)--**
(ligand) transition.
Thus, on the basis of SlXtroscopic (IR, aH NMR, UV/Vis) and conductimetric data alongwith elemental
analysis and FAB mass data, the proposed general structure of the complexes is shown in Figure 1.
s c
N-N 2,2’-bipyridine, (1) and 1,10-phenanthroline, (2)
Figure 1: Proposed structures of Ru(II) complexes
Room temperature emission spectra
Emission properties of the complexes have been studied in acetonitrile solution (10
6 M) at room temperature
(excitation at 450 nm). Complexes did not luminesce most likely due to the efficient migration of the
electron/energy [16-18] from the triplet excited state of Ru" to the ligand, as probability of non-radiative
emission was discarded since complex (2) weakly emitted.
Redox Properties: Redox properties of the ruthenium complexes have been studied in acetonitrile solution
(10
-3 M) in the potential range +/- 2V using Ag/Ag+ as reference and graphite disc as working electrodes.
Oxidation
Redox potential (E) data are reported in Table II. Cyclic voltammogram of the complex (1) showed two
oxidation peaks at 0.88 V and 1.45 V, the former peak being considered to arise from a Ru(II) Ru(III)
oxidation as the latter peak lies in the potential range of ligand oxidation in view of the fact that upon
coordination peaks could be shifted towards less positive potentials. Similarly, in the cyclic voltammogram
(CV) of complex (2) these oxidations occurred at 0.92 V and 1.43 V.
Reduction
During the reduction of the free ligand two peaks were observed at -0.85 and -1.2 V. However, four reduction
peaks were observed at -0.8,-1.1, -1.35 and-1.55 V in the cyclic voltammogram of complex (1). The
reduction peaks at -0.8 and -1.1 V were assigned to arise from ligand reduction whereas the peaks at -1.35
and -1.55 V could "
considered to arise from bipyridine reduction in view of earlier report [19]. Similarly
four reduction peaks at -0.45, -1.2, -1.35 and -1.8 V also arise upon reduction of the complex (2) which were
in consistence with the earlier report [20].
Li
+ binding studies: Due to the presence of a 14-membered ring cavity in the complexes, their binding with
Li
/ on a preliminary level was studied using UV/Vis and electrochemical techniques.
The presence of LiCI (10
"4 M, CH3CN) in the solution of the complexes in acetonitrile (10
5 M) shifted both
the MLCT and intra-ligand transitions towards higher energies along with the increase in their absorbances
(Table III).
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Table II: Electrochemical data* of ligand and Ru(II) complexes inMeCN at 298K
Ligand
[-Ru.L(bpy)2]
2+
[Ru.L(phen)2]
2+
[Ru.L(bpy)2]
2+
+
10
-4 tool dm LiCI
[Ru.L(phen)2]
2+
+
10
-4 mol dm
-3 LiC1
Redox potential
E 298 / V vs Ag/AgC1
Reductions Oxidations
Ru
3+ / Ru2 Ligand
1.55 -0.85, -1.2
0.88 1.45 -0.4, 1.15, 1.45, 1.75
0.92 1.40 -0.45, -1.2, -1.35, -1.8
1.15 1.72 -0.5, 1.08, 1.65
0.95 1.43 -0.5, 1.45, 1.8
* Conditions; solvent, MeCN, supporting electrolyte TBAP (0.1 M); working electrode, graphite disc; auxiliary
electrode, platinum; reference electrode Ag/Ag+. Solute concentration -10"3 M, Eli2 0.5 (Epa + F-,w) where Eva and
Epe anodie and cathodic peak.
Table III: UV-Vis data in MeCN (103M) at 298K for Ru(II) complexes in presence and absence of LiCI
nm (i0’4, e, dm
3 mol-
cm-)
complex Transitions +Lie1 (5 X,! 0=4 moldm-j)
[RuL(bpy)2]* n * (2)
a 246 (7.75) 242 (8.81)
n n* (1)a 290 (6.65) 286 (7.06)
m.l.c.t. 485 (0.83) 476 (0.97)
[RuL(phen)2]
2+ n n* (2) 230 (10.16) 226 (13.95)
n n* (1)a 264 (10.69) 263 (12.04)
m.l.c.t. 417 (0.75) 349 (2.98)
413(1:30)
(1) and (2) used to denote different ligand orbitals.
Electrochemical studies of the complexes 4(1 and 2) in the presence of Li+: As shown in Table III the
addition of a CHaCN solution of LiC1 (10" M) to the complexes (I0 M, CHCN) shifted metal-based
oxidation peak towards a more positive potential by 230 mV in complex (1) whereas in complex (2) shift was
40 mV compared to LiC1 unbound complexes. The larger shift observed for complex (1) as compared to
complex (2) may be considered in view ofmore flexibility of the bipyridine ring.
Thus, in view of these observations and earlier reports [21 binding of Li+ inside the cavity of the macrocycle
could be considered on a preliminary level.
Antitumour and anti-HIV activities
The antitumour and anti-HIV activities were evaluated using standard procedure [22,23]. The cytotoxicity
data of free ligand alongwith their ruthenium complexes are shown in Table IV. The free ligand showed
potential activity against IA9 and A549 which could be considered [24] in view of the significant
bioactivities shown by an earlier ligand system bearing similar functional (-N-C-O) group. However, the
complexes showed a better activity as compared to the free ligand against almost all tumour cells. This
inhibitory behaviour of the complexes may be considered in view of their interaction with DNA as reported
[25,26] earlier. Complex (2) however showed better activity against IA9, KB-VIN and A-549 as compared to
complex (1).
From the anti-HIV data of the ligand and complexes as shown in table IV, it could be seen that complex (1)
show a smaller ICs0 value than the free ligand. However the ECs0 value of the free ligand (13.3 tM) showed
that ligand is more active than the complex (1) which may be understood in terms of steric factors [27].
Complex (2) bearing a bulkier group (1,10-phenanthroline) did not show activities (NA inhibition < or
5% at 20 g/mL). The activity of these compounds has been compared with the standard AZT (azido-
thymidine) treated as control under the similar experimental conditions.
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Table IV: Antitumour* and anti-HIV activity of free ligand and its Ru(II) complexes
Compound Tumour cells
Ht’T:8 IA9 HOS KB KB-VIN MCF-7 A549 U87-MG
Anti-HIV
ICo
L 41.4 37.1 >20 (114) 46.2 50 50 29.1 >20 (60) 48.0
(1) >20(33.3) 10.3 >20(23.9) 14.5 >20(13.6) 16.6 14.9 >20(39.3) 17.7
(2) 13.9 9.7 12.3 13.9 7.2 14.8 9.0 >20 (36.1)
AZT** 1870
* Values are ICs0 concentration in laM.
Note, if inhibition < 50% at 20 microgram per mL, percent inhibition observed is the value in brackets.
Turnout/tissue type; HCT Ileoeeeal, IA9 Ovarian, HOS Bone, KB Nasopharynx, MCF Breast,
A549- lung, U87-MG- Glioblastoma.
o ED 50 in microgram permL is less than 50% at highest test concentration.
** AZT Azido-thymidine; m/z 267.25
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